Bayer Supervisory Board Member Buys Shares in Disclosed Manager Transaction
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Bayer ( (DE:BAYN) ) is now available.
Bayer has disclosed a manager’s transaction under EU market abuse rules, reporting that supervisory board member Prof. Dr. Norbert Winkeljohann purchased Bayer shares on March 5, 2026. The transaction, executed on the Xetra trading platform at an average price of €37.4313 and totaling roughly €99,979 in value, signals personal insider confidence and provides investors with additional transparency on governance-level share dealings.
While modest in size relative to Bayer’s market capitalization, the purchase may be read by some market participants as a vote of confidence in the company’s prospects from a key member of its supervisory body. The disclosure under Article 19 MAR underscores Bayer’s adherence to regulatory requirements on insider dealings and supports market integrity by informing shareholders and analysts about trading activity by top decision-makers.
The most recent analyst rating on (DE:BAYN) stock is a Sell with a EUR36.00 price target. To see the full list of analyst forecasts on Bayer stock, see the DE:BAYN Stock Forecast page.
More about Bayer
Bayer Aktiengesellschaft is a German life-sciences group headquartered in Leverkusen, active primarily in pharmaceuticals, consumer health, and crop science. Its shares, listed under ISIN DE000BAY0017, trade on major regulated markets in Germany, including Frankfurt and Xetra, making it one of the country’s most closely watched blue-chip issuers.
Average Trading Volume: 3,882,322
Technical Sentiment Signal: Hold
Current Market Cap: €37.11B
For an in-depth examination of BAYN stock, go to TipRanks’ Overview page.
